Growth Metrics

Vanda Pharmaceuticals (VNDA) Depreciation & Amortization (CF) (2016 - 2025)

Vanda Pharmaceuticals' Depreciation & Amortization (CF) history spans 16 years, with the latest figure at $304000.0 for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 16.03% to $304000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 22.56% increase, with the full-year FY2025 number at $1.1 million, up 22.56% from a year prior.
  • Depreciation & Amortization (CF) hit $304000.0 in Q4 2025 for Vanda Pharmaceuticals, up from $301000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for VNDA hit a ceiling of $374000.0 in Q4 2021 and a floor of $200000.0 in Q3 2023.
  • Historically, Depreciation & Amortization (CF) has averaged $277000.0 across 5 years, with a median of $287500.0 in 2022.
  • Biggest five-year swings in Depreciation & Amortization (CF): tumbled 33.11% in 2023 and later surged 39.35% in 2025.
  • Tracing VNDA's Depreciation & Amortization (CF) over 5 years: stood at $374000.0 in 2021, then dropped by 24.06% to $284000.0 in 2022, then fell by 27.82% to $205000.0 in 2023, then rose by 27.8% to $262000.0 in 2024, then grew by 16.03% to $304000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for VNDA at $304000.0 in Q4 2025, $301000.0 in Q3 2025, and $267000.0 in Q2 2025.